TIRZEPATIDE PEPTIDE
Tirzepatide is a synthetic 39-amino-acid, lipid-conjugated peptide (CAS 2023788-19-2) engineered as a dual agonist of the GIP and GLP-1 receptors, supplied as a research-grade lyophilized material for laboratory use only.
Tirzepatide is a synthetic 39-amino-acid, lipid-conjugated peptide (CAS 2023788-19-2) engineered as a dual agonist of the GIP and GLP-1 receptors. It is supplied as a research-grade lyophilized material for laboratory use only. Additionally, TIRZEPATIDE PEPTIDE is gaining attention in the field of peptide research.
Molecular profile of TIRZEPATIDE PEPTIDE
| Also known as | GIP/GLP-1 receptor agonist |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | 4813.45 |
| Amino Acid Count | 39 |
| Sequence | 39-residue GIP/GLP-1 dual agonist; Aib at pos 2 & 13-area, Lys20 conjugated to γGlu-(AEEA)2-C20 diacid, C-terminal amide (full sequence per COA) |
| Purity | ≥99% by HPLC · COA available |
| Physical Form | Lyophilized powder |
What is TIRZEPATIDE?
Tirzepatide is a synthetic single-chain polypeptide belonging to the class of incretin-mimetic peptides. It is classified within the GLP-1 category of research compounds as a dual GIP/GLP-1 receptor agonist. It is catalogued under CAS number 2023788-19-2 and carries the molecular formula C225H348N48O68 with an average molecular weight of 4813.45 g/mol.
As a structurally engineered analog, it is investigated in in-vitro incretin-receptor pharmacology and metabolic-signaling research models. Notably, TIRZEPATIDE PEPTIDE serves as a crucial reference in scientific studies.
Structurally, tirzepatide is a 39-residue peptide built on a modified incretin backbone. The sequence incorporates the non-proteinogenic residue 2-aminoisobutyric acid (Aib) at position 2 and in the position-13 region, substitutions that increase conformational rigidity and confer resistance to enzymatic degradation relative to native incretins. The lysine at position 20 is covalently conjugated to a C20 fatty-diacid moiety through a linker composed of a γ-glutamate spacer and two AEEA (8-amino-3,6-dioxaoctanoic acid) units, and the chain terminates in a C-terminal amide. The complete, position-by-position residue sequence is provided on the accompanying certificate of analysis.
This lipidation architecture is a defining feature of the molecule and is the subject of structure-activity study, as the fatty-acid tail is understood in research settings to mediate reversible association with serum albumin, extending the peptide’s circulating profile in experimental systems. Within a strictly research context, tirzepatide is used as a reference agonist for probing GIP and GLP-1 receptor binding, receptor-complex conformation, and downstream cyclic-AMP signaling in cell-based assays. This product is offered for laboratory research use only and is not a drug, food, or cosmetic; it is not intended for diagnostic, therapeutic, or human or veterinary use.
Reconstitution & handling
Tirzepatide is supplied as a lyophilized (freeze-dried) powder. It requires reconstitution in a suitable aqueous solvent before use in laboratory work. Bacteriostatic water (water containing 0.9% benzyl alcohol) and sterile water are the solvents most commonly selected for dissolving lipidated peptides of this class.
Sterile phosphate-buffered solutions may also be used depending on assay requirements. The lyophilate should be brought to room temperature before opening to minimize condensation. The solvent should be introduced slowly by directing it against the inner wall of the vial rather than dispensing it directly onto the powder.
The C20 diacid modification gives tirzepatide surfactant-like, amphipathic character. This means that complete dissolution can be slower than for unmodified peptides and is favored by near-neutral to mildly basic conditions.
A properly reconstituted solution should appear clear and free of visible particulates or persistent turbidity. Reconstitution and any subsequent handling or aliquoting should be performed under clean or aseptic technique to preserve sample integrity for analytical work.
Storage & stability
In its lyophilized form, tirzepatide is stable for extended periods. It should be stored sealed, protected from light and moisture, and kept frozen. Short intervals at refrigerated or ambient temperature during shipping and handling are generally tolerated by the dry powder.
Once reconstituted, the peptide is far less stable and should be maintained refrigerated at approximately 2-8°C for near-term use, with light exposure minimized. For longer retention of reconstituted material, storage frozen in single-use aliquots is preferred.
How it’s tested
Each lot of tirzepatide is characterized analytically and released with a certificate of analysis (COA). This document documents its identity and purity. Chromatographic purity is determined by reversed-phase high-performance liquid chromatography (RP-HPLC), which resolves the target peptide from process-related impurities and truncated or deletion sequences.
Identity and molecular integrity are confirmed by mass spectrometry (typically ESI-MS or MALDI-TOF). The measured mass is compared against the theoretical molecular weight of 4813.45 to verify the intact, correctly conjugated 39-residue structure.
Frequently asked questions
What is tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide (CAS 2023788-19-2) classified as a dual GIP/GLP-1 receptor agonist. It is supplied as a lyophilized research-grade material for laboratory use only and is not intended for human or veterinary use.
What are its molecular formula and weight?
Tirzepatide has the molecular formula C225H348N48O68 and an average molecular weight of 4813.45 g/mol. It comprises 39 amino acid residues, including Aib substitutions and a C20 fatty-diacid conjugated at Lys20 via a γGlu-(AEEA)2 linker, with a C-terminal amide.
What makes tirzepatide structurally distinctive?
Its defining feature is a lipidation architecture: the lysine at position 20 is conjugated to a C20 diacid through a γ-glutamate spacer and two AEEA units. Combined with Aib residues that rigidify the backbone, this gives the peptide amphipathic character studied in structure-activity research.
How is tirzepatide reconstituted?
The lyophilized powder is dissolved in a suitable aqueous solvent such as bacteriostatic or sterile water. Solvent is added slowly against the vial wall and the peptide allowed to dissolve without vigorous shaking, since the fatty-acid conjugation makes it prone to foaming and aggregation under mechanical shear.
How should tirzepatide be stored?
Store the lyophilized powder frozen, sealed, and protected from light and moisture for long-term stability. After reconstitution, keep it refrigerated at 2-8°C for near-term use or frozen in single-use aliquots to avoid repeated freeze-thaw cycles.
How is purity and identity verified?
Each lot is analyzed by reversed-phase HPLC for purity (specification ≥99%) and by mass spectrometry to confirm identity against the theoretical molecular weight of 4813.45. Results are documented on a lot-specific certificate of analysis (COA) available for the batch.
This reference describes the compound’s chemistry and analytical properties for laboratory research use only. It is not medical advice; the product is not a drug, supplement, or cosmetic and is not for human or veterinary consumption. TIRZEPATIDE PEPTIDE is specifically designed for research applications.
